Repurposing antiparasitic benzimidazoles—primarily mebendazole (MBZ) and albendazole (ABZ)—has emerged as a compelling strategy in modern oncology. Because these agents possess decades of well-established clinical safety, broad global availability, and low manufacturing costs, drug repurposing significantly shortens the typical development timeline to Phase II clinical trials (3–5 years).
Rather than acting on a single receptor, these compounds exert multi-targeted antitumor effects across a wide variety of solid and hematological malignancies.
Key Mechanisms of Action
Microtubule Disruption & Mitotic Arrest Both MBZ and ABZ bind to the colchicine-binding site on β-tubulin, inhibiting microtubule polymerization and halting spindle formation. This mechanism closely mirrors classical chemotherapy agents like taxanes and vinca alkaloids, leading to cell-cycle arrest (typically at the G2/M phase) and apoptosis.
Inhibition of Key Oncogenic Signaling Pathways These antiparasitic agents suppress several major signaling networks essential for cancer cell survival and stemness, including Wnt/β-catenin, Hedgehog (via inhibition of the Smoothened receptor and primary cilium formation), STAT3/STAT5, NF-κB, PI3K/Akt/mTOR, and Notch1.
Anti-Angiogenesis & Metabolic Reprogramming MBZ and ABZ downregulate vascular endothelial growth factor (VEGF), VEGFR2, and hypoxia-inducible factor 1-alpha (HIF-1α), suppressing new blood vessel formation and tumor ascites accumulation. Additionally, ABZ blocks glucose uptake, leading to ATP depletion and inhibition of cancer cell glycolysis.
Induction of ROS & Apoptotic Signaling Treatment with these drugs triggers reactive oxygen species (ROS) production and oxidative stress. In the case of ABZ, this includes DNA damage marked by H2AX phosphorylation. Furthermore, MBZ inactivates pro-survival proteins like Bcl-2 and downregulates XIAP, activating caspase cascades.
Overcoming Drug Resistance & Targeting Cancer Stem Cells MBZ and ABZ downregulate the P-glycoprotein (P-gp) drug efflux pump and disrupt cancer stem cell (CSC) populations, re-sensitizing chemoresistant tumors to conventional agents such as paclitaxel, vincristine, temozolomide, cisplatin, and bortezomib.
Immunomodulation MBZ promotes the repolarization of macrophages from a pro-tumor M2 phenotype to an anti-tumor M1 phenotype, upregulates MHC class I expression, and increases CD8+ T-cell infiltration within the tumor microenvironment.
Specific Roles of Mebendazole vs. Albendazole
Mebendazole (MBZ): MBZ is highly lipophilic and successfully crosses the blood-brain barrier. Consequently, it has been actively evaluated in primary brain tumors such as glioblastoma, pediatric high-grade gliomas, and medulloblastoma. Phase 1 trials (such as those at Johns Hopkins) confirmed that high-dose MBZ in combination with temozolomide or re-radiation is safe and well-tolerated. Clinical case studies and trials have also shown disease stabilization or tumor regression in metastatic adrenocortical carcinoma, colorectal cancer, melanoma, and leukemias.
Albendazole (ABZ): ABZ demonstrates strong preclinical antiproliferative effects in colorectal, hepatocellular, triple-negative breast, prostate, head and neck (particularly HPV-negative), and ovarian cancers. ABZ also functions as a radiosensitizer by inducing DNA damage, making it a candidate in combination with radiation therapy for brain metastases from melanoma and small cell lung cancer.
Clinical Challenges & Future Directions
Pharmacokinetics & Bioavailability: Both compounds suffer from poor aqueous solubility, limited gastrointestinal absorption, and extensive hepatic first-pass metabolism, restricting systemic bioavailability.
Dose-Limiting Toxicity: Long-term or high-dose administration of ABZ is frequently limited by myelosuppression and neutropenia. MBZ exhibits a more favorable systemic toxicity profile, although transient elevation of liver enzymes can occur at higher doses.
Combination Approaches & Advanced Delivery: Monotherapy trials in advanced, refractory gastrointestinal cancers showed limited efficacy. Therefore, ongoing research focuses on combination regimens (pairing benzimidazoles with chemotherapy, radiotherapy, or immunotherapy) and nanomedicine formulations (such as polymeric nanoparticles, cyclodextrin complexes, and metal-organic frameworks) to enhance solubility, targeted delivery, and clinical response.
References
Aliabadi, A., Moradi, S. Z., Abdian, S., Fakhri, S., & Echeverría, J. (2025). Critical dysregulated signaling pathways in drug resistance: Highlighting the repositioning of mebendazole for cancer therapy. Frontiers in Pharmacology, 16, Article 1631419. https://doi.org/10.3389/fphar.2025.1631419
Alavi, S. E., & Ebrahimi Shahmabadi, H. (2021). Anthelmintics for drug repurposing: Opportunities and challenges. Saudi Pharmaceutical Journal, 29(5), 434–445. https://doi.org/10.1016/j.jsps.2021.04.004
Al-Zoubi, R. M., Farhan, A., Hanbali, B., Al-Zoubi, S. R., Khan, A., Shkoor, M., Bani-Yaseen, A. D., Al Zoubi, M. S., & Agouni, A. (2026). Antiparasitic agents in oncology: Innovative mechanisms, emerging evidence and clinical potential in cancer treatment. European Journal of Medicinal Chemistry, 316, Article 118987. https://doi.org/10.1016/j.ejmech.2026.118987
Badawy, M. A. S., Bräse, S., Ali, T. F. S., Abdel-Aziz, M., & Abdel-Rahman, H. M. (2025). Biologically active benzimidazole hybrids as cancer therapeutics: Recent advances. Pharmaceuticals, 18(10), Article 1454. https://doi.org/10.3390/ph18101454
Bai, W., Tang, X., Xiao, T., Qiao, Y., Tian, X., Zhu, B., Chen, J., Chen, C., Li, Y., Lin, X., Cai, J., Lin, Y., Zhu, W., Yan, G., Liang, J., & Hu, J. (2024). Enhancing antitumor efficacy of oncolytic virus M1 via albendazole-sustained CD8+ T cell activation. Molecular Therapy Oncology, 32, Article 200813. https://doi.org/10.1016/j.omton.2024.200813
Becerril-Vega, J., Hernández-Campos, A., González-Hernández, I., Flores-Ramos, M., Castillo, R., Leyva-Gómez, G., Mayet-Cruz, L., & Jung-Cook, H. (2023). Development and pharmacokinetic evaluation of two parenteral formulations of albendazole using prodrug and cosolvent approaches. AAPS PharmSciTech, 24(6), Article 158. https://doi.org/10.1208/s12249-023-02613-9
Castro, L. S. E. P. W., Kviecinski, M. R., Ourique, F., Parisotto, E. B., Grinevicius, V. M. A. S., Correia, J. F. G., Wilhelm Filho, D., & Pedrosa, R. C. (2016). Albendazole as a promising molecule for tumor control. Redox Biology, 10, 90–99. https://doi.org/10.1016/j.redox.2016.09.013
Chai, J.-Y., Jung, B.-K., & Hong, S.-J. (2021). Albendazole and mebendazole as anti-parasitic and anti-cancer agents: An update. The Korean Journal of Parasitology, 59(3), 189–225. https://doi.org/10.3347/kjp.2021.59.3.189
Ding, Y., Zhang, Z., Ding, C., Xu, S., & Xu, Z. (2023). The use of cyclodextrin inclusion complexes to increase the solubility and pharmacokinetic profile of albendazole. Molecules, 28(21), Article 7295. https://doi.org/10.3390/molecules28217295
Gallia, G. L., Holdhoff, M., Brem, H., Joshi, A. D., Hann, C. L., Bai, R.-Y., Staedtke, V., Blakeley, J. O., Sengupta, S., Jarrell, T. C., Wollett, J., Szajna, K., Helie, N., Mattox, A. K., Ye, X., Rudek, M. A., & Riggins, G. J. (2021). Mebendazole and re-irradiation, temozolomide, or levamisole/CCNU in patients with recurrent high-grade glioma: Phase 1 clinical trial results. Neuro-Oncology Advances, 3(1), Article vdaa154. https://doi.org/10.1093/noajnl/vdaa154
Ghalehbandi, S., Yuzugulen, J., Pranjol, M. Z. I., & Pourgholami, M. H. (2023). The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. European Journal of Pharmacology, 949, Article 175586. https://doi.org/10.1016/j.ejphar.2023.175586
Golla, U., Patel, S., Shah, N., Talamo, S., Bhalodia, R., Claxton, D., Dovat, S., & Sharma, A. (2024). From deworming to cancer therapy: Benzimidazoles in hematological malignancies. Cancers, 16(20), Article 3454. https://doi.org/10.3390/cancers16203454
Han, Y., & Joo, H.-G. (2020). Involvement of reactive oxygen species in the anti-cancer activity of fenbendazole, a benzimidazole anthelmintic. Korean Journal of Veterinary Research, 60(2), 79–83. https://doi.org/10.14405/kjvr.2020.60.2.79
Huang, H., He, Q., Guo, B., Xu, X., Wu, Y., & Li, X. (2021). Progress in redirecting antiparasitic drugs for cancer treatment. Drug Design, Development and Therapy, 15, 2747–2767. https://doi.org/10.2147/DDDT.S309062
Kim, U., Shin, C., Kim, C.-Y., Ryu, B., Kim, J., Baek, J., & Park, J.-H. (2021). Albendazole exerts antiproliferative effects on prostate cancer cells by inducing reactive oxygen species generation. Oncology Letters, 21(5), Article 356. https://doi.org/10.3892/ol.2021.12656
LeapSpace. (2026). Albendazole and cancer literature compilation: Newest first [Working paper list].
Liaqat, I., Omer, M. O., Rasheed, M. A., & Raza, S. (2024). Preparation, characterization and in vitro anticancer evaluation of albendazole-loaded zinc oxide nanoparticles. Pakistan Veterinary Journal, 44(4), 1338–1344. https://doi.org/10.29261/pakvetj/2024.282
Mansoori, S., Fryknäs, M., Alvfors, C., Loskog, A., Larsson, R., & Nygren, P. (2021). A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer. Scientific Reports, 11, Article 8981. https://doi.org/10.1038/s41598-021-88433-y
Noorani, L., Pourgholami, M. H., Liang, M., Morris, D. L., & Stenzel, M. (2014). Albendazole loaded albumin nanoparticles for ovarian cancer therapy. European Journal of Nanomedicine, 6(4), 227–236. https://doi.org/10.1515/ejnm-2014-0026
Nuciforo, S., Blukacz, L., Heusler, M.-A., Booij, T. H., Kübler, L., Trulsson, F., Boldanova, T., Wang, X., Ketterer, S., Matter, M. S., Stirnimann, C. U., Wieland, S., & Heim, M. H. (2026). Hepatocellular carcinoma organoids enable drug discovery and combination therapy across heterogeneous tumors. Cell Reports, 45(9), Article 117895. https://doi.org/10.1016/j.celrep.2026.117895
Pantziarka, P., Bouche, G., Meheus, L., Sukhatme, V., & Sukhatme, V. P. (2014). Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent. ecancermedicalscience, 8, Article 443. https://doi.org/10.3332/ecancer.2014.443
Patel, K., Doudican, N. A., Schiff, P. B., & Orlow, S. J. (2011). Albendazole sensitizes cancer cells to ionizing radiation. Radiation Oncology, 6, Article 160. https://doi.org/10.1186/1748-717X-6-160
Patil, V. M., Bhelekar, A., Menon, N., Bhattacharjee, A., Simha, V., Abhinav, R., Abhyankar, A., Sridhar, E., Mahajan, A., Puranik, A. D., Purandare, N., Janu, A., Ahuja, A., Krishnatry, R., Gupta, T., & Jalali, R. (2020). Reverse swing-M, phase 1 study of repurposing mebendazole in recurrent high-grade glioma. Cancer Medicine, 9(13), 4676–4685. https://doi.org/10.1002/cam4.3094
Popović, D. J., Poša, M., Popović, K. J., Kolarović, J., Popović, J. K., & Banović, P. Z. (2017). Application of a widely-used tropical anti-worm agent, mebendazole, in modern oncology. Tropical Journal of Pharmaceutical Research, 16(10), 2555–2562. https://doi.org/10.4314/tjpr.v16i10.32
Pourgholami, M. H., Yan, C. M., & Morris, D. L. (2009). Albendazole impairs growth of paclitaxel-resistant ovarian cancer cells. Anticancer Research, 29(10), 3791–3796.
Pourgholami, M. H., Szwajcer, M., & Morris, D. L. (2010). Albendazole causes intracellular ATP depletion and induces apoptosis in human ovarian cancer cells. Anticancer Research, 30(2), 423–428.
Racoviceanu, R., Trandafirescu, C., Voicu, M., Ghiulai, R., Borcan, F., Dehelean, C., Watz, C., Aigner, Z., Ambrus, R., Coricovac, D. E., Cîrcioban, D., Mioc, A., Szuhanek, C. A., & Şoica, C. (2020). Solid polymeric nanoparticles of albendazole: Synthesis, physico-chemical characterization and biological activity. Molecules, 25(21), Article 5130. https://doi.org/10.3390/molecules25215130
Virlley, S., Arya, M., Singh, A., Havelikar, U., Raj, S., Meehnian, H., Dhamija, I., Singh, C., & Kumar, S. (2026). Drug delivery and repurposing approaches for albendazole formulations. BIO Integration, 7(1), Article bioi20250045. https://doi.org/10.15212/bioi20250045
Williamson, T., Bai, R.-Y., Staedtke, V., Huso, D., & Riggins, G. J. (2016). Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model. Oncotarget, 7(42), 68571–68584. https://doi.org/10.18632/oncotarget.11851
Yang, M. H., Ha, I. J., Um, J.-Y., & Ahn, K. S. (2021). Albendazole exhibits anti-neoplastic actions against gastric cancer cells by affecting STAT3 and STAT5 activation by pleiotropic mechanism(s). Biomedicines, 9(4), Article 362. https://doi.org/10.3390/biomedicines9040362